An interventional study of Indoor Air Quality Monitor AirGradient ONE in Smoking, Smoking Cessation and Smoking Reduction, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Prevention
The purpose of this study is to evaluate how using an indoor air quality monitor can promote a smoke-free home for cancer patients who are enrolled in MSK's Tobacco Treatment Program.
1,509 studies on the registry are indexed under Smoking; 193 are open to participants now.
This study's planned enrollment of 10 is below the median of 115 across 1,164 interventional studies indexed under Smoking.
Browse Smoking studies →Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 327 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
10 MSK participants who are current smokers and receiving tobacco treatment will be enrolled.
Other: Indoor Air Quality Monitor AirGradient ONE
Participants will be asked to set up an Indoor Air Quality Monitor AirGradient ONE (Model: I-9PSL) which is an award winning commercially available indoor air quality monitor designed to enable anyone to monitor their air quality in their home for about 60 days (8 weeks). Indoor air pollution levels within participating households will be measured using these AQMs.
Percentage of participants using the air quality monitoring device for 14 consecutive days
Assess the feasibility and acceptability of collecting environmental data on biomarkers of household air quality (AQ) and smoke exposure using low-cost, AQMs as an intermediate endpoint of a smoke-free-home.
Time frame: up to 8 weeks
Percentage of participants who attend the study-specific smoke-free workshop sessions
Assess the feasibility and acceptability of tobacco treatment adherence among individuals diagnosed with cancer.
Time frame: Up to 8 weeks
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →